Clinical Trial Update: Mechlorethamine Induced Contact Dermatitis Avoidance Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing avoidance of mechlorethamine–induced contact dermatitis in patients with cutaneous T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Folliculotropic Mycosis Fungoides
• Granulomatous Slack Skin
• Mycosis Fungoides
• Mycosis Fungoides Variant
• Syringotropic Mycosis Fungoides
• Transformed Mycosis Fungoides

Snippet

Sponsor: Rochester Skin Lymphoma Medical Group, PLLC | Conditions: Cutaneous T-cell Lymphoma, Cutaneous T-cell Lymphoma Stage I | Phase 2 | Status: COMPLETED | Results posted: 2021-11-24